We found that the levels of MAP1B transcripts were significantly higher (by ~1.5-fold) in the ASD population, but not in the BPD or the SCZ populations, compared with the CTR population (Fig. 3a), suggesting that MAP1B-EE might be a convergent molecular signature of both FXS and ASD. Here, MAP1B is linked to fragile X syndrome.